TheProfitWatch

EXEL - Exelixis Inc

Day 1m 10m 60m PreMarket Market AfterHours Gap
39.8 0.23 (0.58%) --- --- --- 0.14 (0.35%) 0.51 (1.29%) 0.0 (0.0%) 0.0 (0.0%)

Exelixis Inc is a biopharmaceutical firm that discovers, develops, and commercializes treatments for cancer. Its molecule, cabozantinib, is indicated for the treatment of patients with metastatic medullary thyroid cancer under the name Cometriq and for the treatment of kidney and liver cancer under the name Cabometyx. Exelixis and its partner Roche have also brought Cotellic to market for the treatment of melanoma.

Category: BIOLOGICAL PRODUCTS, (NO DISGNOSTIC SUBSTANCES)
Market Period: Closed

Earnings & Ratios

Basic EPS:
0.68
Diluted EPS:
0.65
Basic P/E:
58.8676
Diluted P/E:
61.5846
RSI(14) 1m:
100.0
VWAP:
40.03
RVol:
0.5949

Events

Period Kind Movement Occurred At

Related News